

Ekso Bionics(TM) to Present at RoboBusiness Boston Thursday, October 16th

RICHMOND, Calif., Oct. 14, 2014 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (OTCQB:EKSO), a robotic exoskeleton company, announced today that Russ Angold, co-founder and President of Ekso Labs, is a keynote speaker at the RoboBusiness 2014 Conference on Thursday October 16th, at 3:30 pm EDT at the Hynes Convention Center, Boston, MA. Mr. Angold will talk about the history of exoskeletons, how exoskeletons are being used today, and where exoskeletons, or wearable robots, could take us in the future including Medical, Military, Industrial and Consumer applications. Mr. Angold's session titled, "Commercial Opportunities for Exoskeleton Technologies" will also feature a live demonstration of Ekso Bionics' robotic exoskeleton technology.

About Ekso Bionics

Since 2005, Ekso Bionics has been pioneering the field of robotic exoskeletons, or wearable robots, to augment human strength, endurance and mobility. The company's first commercially available product called Ekso has helped thousands of people living with paralysis take millions of steps not otherwise possible. By designing and creating some of the most forward-thinking and innovative solutions for people looking to augment human capabilities, Ekso Bionics is helping people rethink current physical limitations and achieve the remarkable.

Ekso Bionics is headquartered in Richmond, CA and is listed on the OTC QB under the symbol EKSO. To learn more about Ekso Bionics please visit us at www.eksobionics.com

Facebook: www.facebook.com/eksobionics

Twitter: [@eksobionics](https://twitter.com/eksobionics)

YouTube: <https://www.youtube.com/user/EksoBionics/>

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of human exoskeletons, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates

and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain adequate financing to fund the Company's operations and necessary to develop or enhance its technology, the significant length of time and resources associated with the development of our products, the failure to achieve broad market acceptance of the Company's products, the failure of the Company's sales and marketing organization or partners to market its products effectively, adverse results in future clinical studies of the Company's medical products, the failure to obtain or maintain patent protection for the Company's technology, failure to obtain or maintain regulatory approval to market the Company's medical devices, lack of product diversification, volatility in the price of the Company's raw materials, existing or increased competition, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC at <http://www.sec.gov>, including, the Company's Current Report on Form 8-K/A filed on March 31, 2014 and the Company's latest Form 10-Q filed on August 8, 2014. The Company does not undertake to update these forward-looking statements.

CONTACT: Media Contact:

Chantal Beaudry, Managing Director
Phone: 646-871-8480
cbeaudry@lazarpartners.com

Investor Contact:

Lauren Glaser, Vice President
Phone: 646.378.2972
lglaser@troutgroup.com

Source: Ekso Bionics